21 research outputs found
Clinical and virologic outcomes over duration on ART, ARV-naïve patients.
<p>A) median CD4+ cell count (cells/mm<sup>3</sup>) over time on ART; and, B) percentage of patients with virologic suppression (≤400 copies/mL) over time on ART.</p
Median follow-up time on ART by first-line ART regimen, ARV-naïve patients (N = 70,002).
<p>Median follow-up time on ART by first-line ART regimen, ARV-naïve patients (N = 70,002).</p
First-line ART regimen by enrollment year, ARV-naïve patients (N = 70,002).
<p>First-line ART regimen by enrollment year, ARV-naïve patients (N = 70,002).</p
Characterization of treatment failure over time.
<p>A) Virologic and immunologic failure rates over duration on ART, 95% CI; and, B) Percentage of patients with virologic failure within first 18 months on ART by enrollment year.</p
Median age at ART initiation by sex, ARV-naïve patients (N = 70,002).
<p>Median age at ART initiation by sex, ARV-naïve patients (N = 70,002).</p
Immunologic, virologic and adherence patterns by baseline CD4+ cell count, previously ARV-naïve patients (N = 70,002).
<p>Immunologic, virologic and adherence patterns by baseline CD4+ cell count, previously ARV-naïve patients (N = 70,002).</p
Predictors of virologic and immunologic failure for ARV-naïve patients.
<p>Predictors of virologic and immunologic failure for ARV-naïve patients.</p
Flowchart highlighting enrolled patient population.
<p>Flowchart highlighting enrolled patient population.</p
Baseline patient status by enrollment year, ARV-naïve patients.
<p>A) median baseline CD4+cell count (cell/mm<sup>3</sup>); and, B) percentage patients by WHO clinical stage.</p
Detection of EBOV antibodies, Lagos, Nigeria.
<p>(A) Sera samples from 3 EVD survivors, 10 documented EVD contacts, and 6 control HCWs were subjected to LFn-EBOV-GP1 and LFn-EBOV-sGP Western blot analysis. +, positive control. Molecular size marker units are kDa. EVD, Ebola virus disease. Control HCWs, control healthcare workers.</p